Xenopax from a real-world and economic perspective: The future of second-line treatment and prophylaxis for SR-aGVHD
{{output}}
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains a major therapeutic challenge after allogeneic hematopoietic stem cell transplantation. Although ruxolitinib and basiliximab are widely used, their limitations highlight the need for safer, ... ...
